An Early-Phase Clinical Trial Evaluating ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma
Phase of Trial: Phase I/II
Latest Information Update: 03 May 2017
At a glance
- Drugs ABC 294640 (Primary)
- Indications Diffuse large B cell lymphoma; Kaposi's sarcoma
- Focus Adverse reactions
- Sponsors Apogee Biotechnology Corporation; RedHill Biopharma
- 07 Jun 2017 Biomarkers information updated
- 25 Apr 2017 New indication 'kaposi sarcoma' has been added and changes in title, endpoints, patient inclusion criteria also.
- 25 Apr 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2019.